PTPN11 and neuroblastoma: It was found that the frequency of mutations in the RAS-MAPK signaling pathway was significantly increased in relapsed neuroblastoma tumors, including mutations in ALK, NF1, BRAF, PTPN11, FGFR1, and the three RAS genes, and that the mutations in this pathway were mutually exclusive (69).